Edwards Lifesciences (EW) reported Q1 adjusted earnings late Wednesday of $0.64, up from $0.55 a year earlier.

Analysts polled by FactSet expected $0.60.

Net sales for the quarter ended March 31 were $1.41 billion, up from $1.33 billion a year earlier.

Analysts polled by FactSet expected $1.40 billion.

The company said it expects Q2 adjusted EPS of $0.59 to $0.65 on sales of $1.45 billion to $1.53 billion. Analysts polled by FactSet project $0.62 and $1.46 billion, respectively.

For full-year 2025, Edwards reaffirmed adjusted EPS guidance of $2.40 to $2.50. The company said it raised sales guidance for the year to a range of $5.7 billion to $6.1 billion. Analysts polled by FactSet expect adjusted EPS of $2.46 on sales of $5.82 billion.